Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
doi: 10.1210/en.2013-1839 101 Martnez De MorentinPBGonzlez-GarcaIMartinsLLageRFernndez-MalloDMartnez-SnchezNet al
Our findings build on previous research showing high discontinuation rates, particularly among individuals using GLP-1 RAs for weight management ( 10 ), and provide new insights into how and why these medications are stopped in real-world clinical settings
However, injection anxiety should also be put in context
Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG
Some are also approved to treat obesity in people who meet certain medical criteria: Obesity (having a body mass index (BMI) of 30 or higher) OR Overweight (having a BMI of 27 or higher) with a weight-related health issue such as high cholesterol, high blood pressure, or type 2 diabetes Research has found some GLP-1s may help reduce the risk of: Heart attack, stroke, and death in adults with type 2 diabetes and heart disease Chronic kidney disease In addition, some GLP-1s have been approved to treat moderate to severe sleep apnea in adults with obesity
